SlideShare une entreprise Scribd logo
1  sur  17
Assessment of Co-Dependent
       Technologies

Martina Garau and Adrian Towse
  Office of Health Economics
  ISPOR 15th Annual European Congress
            Berlin, Germany
           6 November 2012
Definition of co-dependent technologies
• Technologies, such as diagnostic- treatments (Dx-Tx) pairs,
  to use in combination to achieve or improve clinical benefits
• In particular, a diagnostic test (Dx) can be used to identify
  patients most likely to:
   • Respond or to fail to respond to a drug (personalised medicine)
   • Exhibit adverse events
   But also can be used to:
   • Monitor responses to drugs
   • Determine the risk of developing a disease
The issue of attribution of value of co-
          dependent technologies
• The value created is a “joint product” and there are no
  rules for the attribution of the value to one or the other
• Garrison and Austin (2007) pointed out that how value is
  allocated across patients, payers, Dx manufactures and Tx
  manufacturers depends on the institutional context
   • E.g. whether the Tx was priced before the Dx was
      available, the relative strength of intellectual property
      protection for Dx and Tx
• This will have consequences in terms of incentives for
  evidence generation and subsequent innovation
Framework to assess value of co-dependent
              technologies
                                 1. Reducing
                                     drug
                                   adverse
                                    effects


                                                       2. Reducing
         5.Reducing
                                                       time delays
         uncertainty
                                                       in selecting
         about value
                                                        optimal Tx
                                 Value

                4. Enabling Tx                 3.Increasing
                effective in a
                small fraction
                                                adherence
                 to be made                         or
                   available                   willingness
                                                to start Tx
1. Reducing or avoiding drug adverse effects
Availability of Dx can improve average benefit-risk ratio
so, depending on the severity of side effects,
• Tx obtains marketing authorisation, or
• Use of a licensed Tx in clinical practice increases
Example
• HLA-B*5701 is an allele associated with hypersensitivity
  to abacavir for HIV-1
• Identification of the marker has increased prescribing of
  abacavir, which now is recommended for HLA-B*5701-
  negative patients in European and US guidelines
2. Reducing time delays in selecting optimal Tx
Identifying non-responders and switching them to an
alternative treatment regime/care can
• Improve survival and/or quality of life (particularly in diseases
  at advanced stages)
• Avoid or reduce the cost of treating non-responders
• Avoid or reduce inconvenience to patients


Example
• BCR-ABL test identify chronic myelogenous leukemia (CML)
  patients who are receiving treatment but not responding to it.
   • Can prevent the disease from progressing to blast crisis and death;
     allows ceasing first-line treatment when no longer effective
3.Increasing adherence or willingness to
         undertake Tx or other interventions
Patients are more motivated if they know (ex-ante) the
intervention is likely to work
Issue of non-responders who might experience disutility
(they can feel ‘left-behind’)

Example
• PreDx Diabetes Risk test estimates the patient’s risk for
  developing Type 2 diabetes over the next five years
• This can help encourage patients to follow a healthy lifestyle
  and take other preventive measures.
4. Enabling Tx effective in a small fraction to be
                  made available
A biomarker or other genetic characteristic allowing for
patient stratification can

• “Rescue” Tx that otherwise may either not have been licensed or
  have been withdrawn
• Increase the chance of a Tx meeting reimbursement criteria (if
  targeting responders improves cost effectiveness)
• Accelerate R&D process of Tx (if stratification ascertained at an early
  development stage)
4. Enabling Tx effective in a small fraction to be
            made available: examples
• Gefitinib for non-small-cell lung cancer (NSCLC) initially licensed, then
  withdrawn when Phase III failed to show a survival benefit. With the
  identification of EGFR mutations and its association with response rate to
  TKIs, gefitinib was approved in the EU and other markets in combination with
  the EGFR mutation test.

• NICE recommended trastuzumab for advanced and early-stage breast cancer
  in HER2/neu positive patients identified with HER2/neu test . The Dx-Tx cost
  per QALY was found below the standard threshold.

• Crizotinib targets a small subset of NSCLC patients with an ALK-positive
  molecular abnormality. The development of the ALK FISH test has
  accelerated the development process and increased the likelihood of
  crizotinib delivering health benefits and commercial value
5.Reducing uncertainty about value
• Uncertainty around expected health effects and costs. It influences
  the risk of poor value for money for payers
• Value of information to patients as to their medical condition
  independent of the health outcomes
   •   Effect of reassurance, reduction in patients’ anxiety (measured by EQ-
       5D?)
   •   Dx results also can enable lifestyle choices and planning


• Example
• Oncotype DX ® and MammaPrint ® are multi-gene assays estimating
  the risk of recurrence in breast cancer patients following surgery
• They can guide intervention decisions and reduce the risk of
  dispensing unnecessary chemotherapy (reduce resource costs to the
  health care system and adverse effect for the patient)
Other factors affecting value of
                 combined use of Dx-Tx
• Low accuracy of Dx will decrease potential net gains to patients and
  health care system
    • False positive and false negative patients will miss the opportunity to
      receive a clinical decision from which they can benefit
    • Impact of misdiagnosis varies depending on the location in the treatment
      pathway (1st line, 2nd, last line) and the effectiveness of the alternative
      intervention/s


• If the Tx is licenced also for un-tested populations, Tx can be more
  cost effective when used on its own:
    • When Dx does not provide binary response, if the size of the subset for
      which the Dx does not provide clear-cut result is large relatively to the
      other two subsets and the Dx cost is high compared to the Tx cost
    • When Dx is not accurate
Proposed institutional processes for
            co-dependent technologies
• A joint Dx-Tx review of “at launch” technologies, to be done
  by a drug committee to exploit synergies across Dx and Tx
   • However, need to address the lack of expertise of most drug
     committees in the Dx area
• A separate Dx committee to develop Dx-specific expertise and
  to assess multiple tests with similar clinical use
   • However, may be a trade-off if there are not enough decisions to
     justify a distinct committee
• A comprehensive and consistent approach to assessing value
  of both Dx and Tx
International experience: The case of Australia
• Until now, Dx and associated Tx assessed via different
  committees (MSAC and PBAC)
   • No clear structure for consideration of the interactions and
     benefits from joint use

• New coordinated process and decision framework
  for “co-dependent technologies”
   • “Integrated” applications combining information from Dx
     and Tx manufacturers
   • Reimbursement decisions are made jointly by PBAC and
     MSAC to ensure optimal clinical use (Merlin et al., 2012)
International experience:
      The case of NICE in England and Wales
• NICE has dedicated-process for stand-alone Dx, which follows
  that used for drugs very closely
   • Strong preference for measuring health gains with the QALY
   • Value dimensions beyond health effects, such as value of information
     to patients and process-related benefits, are not factored in explicitly


• “At launch” combinations are appraised via the drug review
  programme (TAs)
   • No explicit consideration of test-related parameters (accuracy, costs)
   • Value dimensions beyond health effects are not factored in explicitly
Conclusions
• The use of Dx-Tx combinations can deliver health gains and cost
  savings within the healthcare systems but also generate broader
  benefits to patients and society

• To ensure efficient use of limited resources health decision makers
  should take account of the full value generated by health
  technologies

• Clear incentives need to be created to encourage evidence collection

• HTA and other decision making systems need coordinated and
  consistent approach to assessing value of Dx and Tx
References
Garau, M., Towse, A., Garrison, L., Housman, L., and Ossa, D. (2012)
Can and should value based pricing be applied to molecular
diagnostics? Research paper 12/03. London: Office of Health
Economics [available free at www.ohe.org]

Garrison, L.P. and Austin, M.J.F. (2007) The economics of personalized
medicine: A model of incentives for value creation and capture. Drug
Information Journal. 41(4), 501-509.

Merlin, T. et al. (2012) Assessing personalized medicines in Australia: A
national framework for reviewing codependent technologies. Medical
Decision Making. Online before print: doi:10.1177/0272989X12452341
To enquire about additional information and analyses, please
contact Martina Garau at mgarau@ohe.org

To keep up with the latest news and research, subscribe to our blog, OHE
News
Follow us on Twitter @OHENews, LinkedIn and SlideShare

Office of Health Economics (OHE)
Southside, 7th Floor
105 Victoria Street
London SW1E 6QT
United Kingdom
+44 20 7747 8850
www.ohe.org
OHE’s publications may be downloaded free of charge for registered users of its
website.

©2012 OHE

Contenu connexe

Tendances

Medical device as per india and usa special reference with 510(k)
Medical device as per india and usa special reference with 510(k)Medical device as per india and usa special reference with 510(k)
Medical device as per india and usa special reference with 510(k)vikash vyas
 
How FDA will reject non compliant electronic submission
How FDA will reject non compliant electronic submissionHow FDA will reject non compliant electronic submission
How FDA will reject non compliant electronic submissionKevin Lee
 
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_finalPpt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_finalRajashri Survase Ojha
 
DSMB - The Medical Perspective
DSMB - The Medical PerspectiveDSMB - The Medical Perspective
DSMB - The Medical PerspectiveBBCR Consulting
 
Global Clinical Research - South Korea
Global Clinical Research - South KoreaGlobal Clinical Research - South Korea
Global Clinical Research - South KoreaAdam W. Kwan
 
Emerging Trends in Clinical Data Management
Emerging Trends in Clinical Data ManagementEmerging Trends in Clinical Data Management
Emerging Trends in Clinical Data ManagementArshad Mohammed
 
Merck - Vioxx Controversy
Merck - Vioxx ControversyMerck - Vioxx Controversy
Merck - Vioxx ControversyTyler2191
 
CRO and Vendor Oversight: Clinical
CRO and Vendor Oversight: ClinicalCRO and Vendor Oversight: Clinical
CRO and Vendor Oversight: ClinicalManjusha Chowdhury
 
KOL Relationship & Brand Building in Pharma Marketing
KOL Relationship & Brand Building in Pharma MarketingKOL Relationship & Brand Building in Pharma Marketing
KOL Relationship & Brand Building in Pharma MarketingAnjali Makhijani
 
Fda med watch
Fda med watchFda med watch
Fda med watchSridhar S
 
When do drug patents expire and when can generic drugs launch?
When do drug patents expire and when can generic drugs launch?When do drug patents expire and when can generic drugs launch?
When do drug patents expire and when can generic drugs launch?thinkBiotech
 
Marketing Mix, PLC, SWOT Analysis - LIPITOR
Marketing Mix, PLC, SWOT Analysis - LIPITORMarketing Mix, PLC, SWOT Analysis - LIPITOR
Marketing Mix, PLC, SWOT Analysis - LIPITORJ. D. Chudasama
 
curled-metal case study analysis
curled-metal case study analysiscurled-metal case study analysis
curled-metal case study analysisancientsoul90
 
Anda submissions – refuse to-receive standards
Anda submissions – refuse to-receive standards Anda submissions – refuse to-receive standards
Anda submissions – refuse to-receive standards Rumel Dey
 
NDA Application.pptx
NDA Application.pptxNDA Application.pptx
NDA Application.pptxVenugopal N
 
9th Medical Science Liaison Best Practices
9th Medical Science Liaison Best Practices9th Medical Science Liaison Best Practices
9th Medical Science Liaison Best PracticesExL Pharma
 

Tendances (20)

Medical device as per india and usa special reference with 510(k)
Medical device as per india and usa special reference with 510(k)Medical device as per india and usa special reference with 510(k)
Medical device as per india and usa special reference with 510(k)
 
How FDA will reject non compliant electronic submission
How FDA will reject non compliant electronic submissionHow FDA will reject non compliant electronic submission
How FDA will reject non compliant electronic submission
 
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_finalPpt 1 overview of regulatory affairs and diff bodies_august2016_final
Ppt 1 overview of regulatory affairs and diff bodies_august2016_final
 
DSMB - The Medical Perspective
DSMB - The Medical PerspectiveDSMB - The Medical Perspective
DSMB - The Medical Perspective
 
Global Clinical Research - South Korea
Global Clinical Research - South KoreaGlobal Clinical Research - South Korea
Global Clinical Research - South Korea
 
Emerging Trends in Clinical Data Management
Emerging Trends in Clinical Data ManagementEmerging Trends in Clinical Data Management
Emerging Trends in Clinical Data Management
 
Merck - Vioxx Controversy
Merck - Vioxx ControversyMerck - Vioxx Controversy
Merck - Vioxx Controversy
 
CRO and Vendor Oversight: Clinical
CRO and Vendor Oversight: ClinicalCRO and Vendor Oversight: Clinical
CRO and Vendor Oversight: Clinical
 
KOL Relationship & Brand Building in Pharma Marketing
KOL Relationship & Brand Building in Pharma MarketingKOL Relationship & Brand Building in Pharma Marketing
KOL Relationship & Brand Building in Pharma Marketing
 
Fda med watch
Fda med watchFda med watch
Fda med watch
 
When do drug patents expire and when can generic drugs launch?
When do drug patents expire and when can generic drugs launch?When do drug patents expire and when can generic drugs launch?
When do drug patents expire and when can generic drugs launch?
 
Japanese regulatory affairs
Japanese regulatory affairsJapanese regulatory affairs
Japanese regulatory affairs
 
Para i iv orange book
Para i iv orange bookPara i iv orange book
Para i iv orange book
 
Marketing Mix, PLC, SWOT Analysis - LIPITOR
Marketing Mix, PLC, SWOT Analysis - LIPITORMarketing Mix, PLC, SWOT Analysis - LIPITOR
Marketing Mix, PLC, SWOT Analysis - LIPITOR
 
case study-pharma
case study-pharmacase study-pharma
case study-pharma
 
curled-metal case study analysis
curled-metal case study analysiscurled-metal case study analysis
curled-metal case study analysis
 
Anda submissions – refuse to-receive standards
Anda submissions – refuse to-receive standards Anda submissions – refuse to-receive standards
Anda submissions – refuse to-receive standards
 
NDA Application.pptx
NDA Application.pptxNDA Application.pptx
NDA Application.pptx
 
Ctd
CtdCtd
Ctd
 
9th Medical Science Liaison Best Practices
9th Medical Science Liaison Best Practices9th Medical Science Liaison Best Practices
9th Medical Science Liaison Best Practices
 

Similaire à Implications of Co-Dependent Technologies in Medicine

Apr 13 improving methods and processes codependent techs mg
Apr 13 improving methods and processes codependent techs mgApr 13 improving methods and processes codependent techs mg
Apr 13 improving methods and processes codependent techs mgOffice of Health Economics
 
Improving Methods and Processes for Assessing Codependent Technologies
Improving Methods and Processes for Assessing Codependent TechnologiesImproving Methods and Processes for Assessing Codependent Technologies
Improving Methods and Processes for Assessing Codependent TechnologiesOffice of Health Economics
 
Reimbursement Strategy for Companion Diagnostics
Reimbursement Strategy for Companion DiagnosticsReimbursement Strategy for Companion Diagnostics
Reimbursement Strategy for Companion DiagnosticsEdward Berger
 
Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?Office of Health Economics
 
Regulation of cell and tissue therapies and clinical research in Australia
Regulation of cell and tissue therapies and clinical research in AustraliaRegulation of cell and tissue therapies and clinical research in Australia
Regulation of cell and tissue therapies and clinical research in AustraliaTGA Australia
 
Evaluating the impact of HTA and ‘better decision-making’ on health outcomes
Evaluating the impact of HTA and ‘better decision-making’ on health outcomesEvaluating the impact of HTA and ‘better decision-making’ on health outcomes
Evaluating the impact of HTA and ‘better decision-making’ on health outcomescheweb1
 
Use of real-world data to provide evidence in.pptx
Use of real-world data to provide evidence in.pptxUse of real-world data to provide evidence in.pptx
Use of real-world data to provide evidence in.pptxDrPallaviKalbande1
 
Randomization in Clinical Trials.pptx
Randomization in Clinical Trials.pptxRandomization in Clinical Trials.pptx
Randomization in Clinical Trials.pptxdivya87486
 
Stratified Medicine
Stratified MedicineStratified Medicine
Stratified MedicineEuroBioForum
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canadian Organization for Rare Disorders
 
Innovent Oncology Program Sheets
Innovent Oncology Program SheetsInnovent Oncology Program Sheets
Innovent Oncology Program SheetsKirby Ryan, Jr.
 
An Interpretive Review Of Consensus Statements On Clinical Guideline Developm...
An Interpretive Review Of Consensus Statements On Clinical Guideline Developm...An Interpretive Review Of Consensus Statements On Clinical Guideline Developm...
An Interpretive Review Of Consensus Statements On Clinical Guideline Developm...Lori Moore
 
Addressing the unpredictability issues in cancer vaccine trials
Addressing the unpredictability issues in cancer vaccine trialsAddressing the unpredictability issues in cancer vaccine trials
Addressing the unpredictability issues in cancer vaccine trialsBhaswat Chakraborty
 
Cadth 2015 e2 dd systemic review-ohtac aug13-2013_2
Cadth 2015 e2 dd systemic review-ohtac aug13-2013_2Cadth 2015 e2 dd systemic review-ohtac aug13-2013_2
Cadth 2015 e2 dd systemic review-ohtac aug13-2013_2CADTH Symposium
 
Interview Question Series: Clinical Research
Interview Question Series: Clinical ResearchInterview Question Series: Clinical Research
Interview Question Series: Clinical ResearchClinosolIndia
 
Clinical trial design, Trial Size, and Study Population
Clinical trial design, Trial Size, and Study Population Clinical trial design, Trial Size, and Study Population
Clinical trial design, Trial Size, and Study Population Shubham Chinchulkar
 

Similaire à Implications of Co-Dependent Technologies in Medicine (20)

Apr 13 improving methods and processes codependent techs mg
Apr 13 improving methods and processes codependent techs mgApr 13 improving methods and processes codependent techs mg
Apr 13 improving methods and processes codependent techs mg
 
Improving Methods and Processes for Assessing Codependent Technologies
Improving Methods and Processes for Assessing Codependent TechnologiesImproving Methods and Processes for Assessing Codependent Technologies
Improving Methods and Processes for Assessing Codependent Technologies
 
Reimbursement Strategy for Companion Diagnostics
Reimbursement Strategy for Companion DiagnosticsReimbursement Strategy for Companion Diagnostics
Reimbursement Strategy for Companion Diagnostics
 
Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
Can the US Afford to Ignore Cost-effectiveness Evidence in Health Care?
 
Regulation of cell and tissue therapies and clinical research in Australia
Regulation of cell and tissue therapies and clinical research in AustraliaRegulation of cell and tissue therapies and clinical research in Australia
Regulation of cell and tissue therapies and clinical research in Australia
 
Evaluating the impact of HTA and ‘better decision-making’ on health outcomes
Evaluating the impact of HTA and ‘better decision-making’ on health outcomesEvaluating the impact of HTA and ‘better decision-making’ on health outcomes
Evaluating the impact of HTA and ‘better decision-making’ on health outcomes
 
Use of real-world data to provide evidence in.pptx
Use of real-world data to provide evidence in.pptxUse of real-world data to provide evidence in.pptx
Use of real-world data to provide evidence in.pptx
 
Randomization in Clinical Trials.pptx
Randomization in Clinical Trials.pptxRandomization in Clinical Trials.pptx
Randomization in Clinical Trials.pptx
 
Stratified Medicine
Stratified MedicineStratified Medicine
Stratified Medicine
 
Abpi rd conference_towse_ 20_nov_2014
Abpi rd conference_towse_ 20_nov_2014Abpi rd conference_towse_ 20_nov_2014
Abpi rd conference_towse_ 20_nov_2014
 
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
Canada’s Orphan Drug Regulatory Framework & panCanadian Access to Rare Diseas...
 
PMED: APPM Workshop: Challenges in Using Bayesian Analysis Approaches for Reg...
PMED: APPM Workshop: Challenges in Using Bayesian Analysis Approaches for Reg...PMED: APPM Workshop: Challenges in Using Bayesian Analysis Approaches for Reg...
PMED: APPM Workshop: Challenges in Using Bayesian Analysis Approaches for Reg...
 
Innovent Oncology Program Sheets
Innovent Oncology Program SheetsInnovent Oncology Program Sheets
Innovent Oncology Program Sheets
 
Towse NDDP implications for drug development
Towse NDDP implications for drug developmentTowse NDDP implications for drug development
Towse NDDP implications for drug development
 
An Interpretive Review Of Consensus Statements On Clinical Guideline Developm...
An Interpretive Review Of Consensus Statements On Clinical Guideline Developm...An Interpretive Review Of Consensus Statements On Clinical Guideline Developm...
An Interpretive Review Of Consensus Statements On Clinical Guideline Developm...
 
Addressing the unpredictability issues in cancer vaccine trials
Addressing the unpredictability issues in cancer vaccine trialsAddressing the unpredictability issues in cancer vaccine trials
Addressing the unpredictability issues in cancer vaccine trials
 
Pragmatic trial.pptx
Pragmatic trial.pptxPragmatic trial.pptx
Pragmatic trial.pptx
 
Cadth 2015 e2 dd systemic review-ohtac aug13-2013_2
Cadth 2015 e2 dd systemic review-ohtac aug13-2013_2Cadth 2015 e2 dd systemic review-ohtac aug13-2013_2
Cadth 2015 e2 dd systemic review-ohtac aug13-2013_2
 
Interview Question Series: Clinical Research
Interview Question Series: Clinical ResearchInterview Question Series: Clinical Research
Interview Question Series: Clinical Research
 
Clinical trial design, Trial Size, and Study Population
Clinical trial design, Trial Size, and Study Population Clinical trial design, Trial Size, and Study Population
Clinical trial design, Trial Size, and Study Population
 

Plus de Office of Health Economics

OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOffice of Health Economics
 
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowsePricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowseOffice of Health Economics
 
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...Office of Health Economics
 
The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...Office of Health Economics
 
ISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isOffice of Health Economics
 
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Office of Health Economics
 
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY? IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?Office of Health Economics
 
Understanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleUnderstanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleOffice of Health Economics
 
Novel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeNovel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeOffice of Health Economics
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Office of Health Economics
 
HTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMRHTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMROffice of Health Economics
 
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Office of Health Economics
 
Pay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandPay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandOffice of Health Economics
 
Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Office of Health Economics
 
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...Office of Health Economics
 

Plus de Office of Health Economics (20)

Annual lecture
Annual lecture Annual lecture
Annual lecture
 
Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20 Devlin ispor 2020 issues panel 20.05.20
Devlin ispor 2020 issues panel 20.05.20
 
Towse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne finalTowse 2020 antimicrobials melbourne final
Towse 2020 antimicrobials melbourne final
 
Towse cgd price transparency seminar
Towse cgd price transparency seminarTowse cgd price transparency seminar
Towse cgd price transparency seminar
 
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian TowseOHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
OHE presents at G20 AMR-R&D meeting in Paris - Adrian Towse
 
Pricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian TowsePricing in emerging markets: options to get value for money - Adrian Towse
Pricing in emerging markets: options to get value for money - Adrian Towse
 
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...% GDP spending in UK, G5 countries and OECD upper middle income countries.  W...
% GDP spending in UK, G5 countries and OECD upper middle income countries. W...
 
The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...The role of real world data and evidence in building a sustainable & efficien...
The role of real world data and evidence in building a sustainable & efficien...
 
ISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money isISPOR Education Symposium- Go where the money is
ISPOR Education Symposium- Go where the money is
 
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
Role Substitution, Skill Mix, and Provider Efficiency and Effectiveness : Les...
 
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY? IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
IS INDICATION BASED PRICING FEASIBLE AND/OR BENEFICIAL FOR SOCIETY?
 
Ispor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-MollaIspor 2019 poster - Patricia Cubi-Molla
Ispor 2019 poster - Patricia Cubi-Molla
 
Understanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to peopleUnderstanding what aspects of health and quality of life are important to people
Understanding what aspects of health and quality of life are important to people
 
Novel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of lifeNovel approaches for valuing health at the end of life
Novel approaches for valuing health at the end of life
 
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
Assessing the Life-Cycle Value Added of Second Generation Antipsychotics in S...
 
HTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMRHTA and payment mechanisms for new drugs to tackle AMR
HTA and payment mechanisms for new drugs to tackle AMR
 
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
Assessing the Life-cycle Value Added of Second-Generation Antipsychotics in S...
 
Pay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in EnglandPay for Performance for Specialised Care in England
Pay for Performance for Specialised Care in England
 
Real option value drugs: is it really an option?
Real option value drugs: is it really an option?Real option value drugs: is it really an option?
Real option value drugs: is it really an option?
 
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
MCDA OR WEIGHTED CEA BASED ON THE QALY? WHICH IS THE FUTURE FOR HTA DECISION ...
 

Dernier

pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologyDeepakDaniel9
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communicationskatiequigley33
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxNaveenkumar267201
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisSujoy Dasgupta
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfDolisha Warbi
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...Sujoy Dasgupta
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptPradnya Wadekar
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.whalesdesign
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.kishan singh tomar
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectiondrhanifmohdali
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 

Dernier (20)

pA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacologypA2 value, Schild plot and pD2 values- applications in pharmacology
pA2 value, Schild plot and pD2 values- applications in pharmacology
 
Using Data Visualization in Public Health Communications
Using Data Visualization in Public Health CommunicationsUsing Data Visualization in Public Health Communications
Using Data Visualization in Public Health Communications
 
Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...Rheumatoid arthritis Part 1, case based approach with application of the late...
Rheumatoid arthritis Part 1, case based approach with application of the late...
 
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptxBreast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
Breast cancer -ONCO IN MEDICAL AND SURGICAL NURSING.pptx
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Adenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosisAdenomyosis or Fibroid- making right diagnosis
Adenomyosis or Fibroid- making right diagnosis
 
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdfPAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
PAIN/CLASSIFICATION AND MANAGEMENT OF PAIN.pdf
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio..."Radical excision of DIE in subferile women with deep infiltrating endometrio...
"Radical excision of DIE in subferile women with deep infiltrating endometrio...
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
Unit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.pptUnit I herbs as raw materials, biodynamic agriculture.ppt
Unit I herbs as raw materials, biodynamic agriculture.ppt
 
MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.MedMatch: Your Health, Our Mission. Pitch deck.
MedMatch: Your Health, Our Mission. Pitch deck.
 
Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.Different drug regularity bodies in different countries.
Different drug regularity bodies in different countries.
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
AORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissectionAORTIC DISSECTION and management of aortic dissection
AORTIC DISSECTION and management of aortic dissection
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 

Implications of Co-Dependent Technologies in Medicine

  • 1. Assessment of Co-Dependent Technologies Martina Garau and Adrian Towse Office of Health Economics ISPOR 15th Annual European Congress Berlin, Germany 6 November 2012
  • 2. Definition of co-dependent technologies • Technologies, such as diagnostic- treatments (Dx-Tx) pairs, to use in combination to achieve or improve clinical benefits • In particular, a diagnostic test (Dx) can be used to identify patients most likely to: • Respond or to fail to respond to a drug (personalised medicine) • Exhibit adverse events But also can be used to: • Monitor responses to drugs • Determine the risk of developing a disease
  • 3. The issue of attribution of value of co- dependent technologies • The value created is a “joint product” and there are no rules for the attribution of the value to one or the other • Garrison and Austin (2007) pointed out that how value is allocated across patients, payers, Dx manufactures and Tx manufacturers depends on the institutional context • E.g. whether the Tx was priced before the Dx was available, the relative strength of intellectual property protection for Dx and Tx • This will have consequences in terms of incentives for evidence generation and subsequent innovation
  • 4. Framework to assess value of co-dependent technologies 1. Reducing drug adverse effects 2. Reducing 5.Reducing time delays uncertainty in selecting about value optimal Tx Value 4. Enabling Tx 3.Increasing effective in a small fraction adherence to be made or available willingness to start Tx
  • 5. 1. Reducing or avoiding drug adverse effects Availability of Dx can improve average benefit-risk ratio so, depending on the severity of side effects, • Tx obtains marketing authorisation, or • Use of a licensed Tx in clinical practice increases Example • HLA-B*5701 is an allele associated with hypersensitivity to abacavir for HIV-1 • Identification of the marker has increased prescribing of abacavir, which now is recommended for HLA-B*5701- negative patients in European and US guidelines
  • 6. 2. Reducing time delays in selecting optimal Tx Identifying non-responders and switching them to an alternative treatment regime/care can • Improve survival and/or quality of life (particularly in diseases at advanced stages) • Avoid or reduce the cost of treating non-responders • Avoid or reduce inconvenience to patients Example • BCR-ABL test identify chronic myelogenous leukemia (CML) patients who are receiving treatment but not responding to it. • Can prevent the disease from progressing to blast crisis and death; allows ceasing first-line treatment when no longer effective
  • 7. 3.Increasing adherence or willingness to undertake Tx or other interventions Patients are more motivated if they know (ex-ante) the intervention is likely to work Issue of non-responders who might experience disutility (they can feel ‘left-behind’) Example • PreDx Diabetes Risk test estimates the patient’s risk for developing Type 2 diabetes over the next five years • This can help encourage patients to follow a healthy lifestyle and take other preventive measures.
  • 8. 4. Enabling Tx effective in a small fraction to be made available A biomarker or other genetic characteristic allowing for patient stratification can • “Rescue” Tx that otherwise may either not have been licensed or have been withdrawn • Increase the chance of a Tx meeting reimbursement criteria (if targeting responders improves cost effectiveness) • Accelerate R&D process of Tx (if stratification ascertained at an early development stage)
  • 9. 4. Enabling Tx effective in a small fraction to be made available: examples • Gefitinib for non-small-cell lung cancer (NSCLC) initially licensed, then withdrawn when Phase III failed to show a survival benefit. With the identification of EGFR mutations and its association with response rate to TKIs, gefitinib was approved in the EU and other markets in combination with the EGFR mutation test. • NICE recommended trastuzumab for advanced and early-stage breast cancer in HER2/neu positive patients identified with HER2/neu test . The Dx-Tx cost per QALY was found below the standard threshold. • Crizotinib targets a small subset of NSCLC patients with an ALK-positive molecular abnormality. The development of the ALK FISH test has accelerated the development process and increased the likelihood of crizotinib delivering health benefits and commercial value
  • 10. 5.Reducing uncertainty about value • Uncertainty around expected health effects and costs. It influences the risk of poor value for money for payers • Value of information to patients as to their medical condition independent of the health outcomes • Effect of reassurance, reduction in patients’ anxiety (measured by EQ- 5D?) • Dx results also can enable lifestyle choices and planning • Example • Oncotype DX ® and MammaPrint ® are multi-gene assays estimating the risk of recurrence in breast cancer patients following surgery • They can guide intervention decisions and reduce the risk of dispensing unnecessary chemotherapy (reduce resource costs to the health care system and adverse effect for the patient)
  • 11. Other factors affecting value of combined use of Dx-Tx • Low accuracy of Dx will decrease potential net gains to patients and health care system • False positive and false negative patients will miss the opportunity to receive a clinical decision from which they can benefit • Impact of misdiagnosis varies depending on the location in the treatment pathway (1st line, 2nd, last line) and the effectiveness of the alternative intervention/s • If the Tx is licenced also for un-tested populations, Tx can be more cost effective when used on its own: • When Dx does not provide binary response, if the size of the subset for which the Dx does not provide clear-cut result is large relatively to the other two subsets and the Dx cost is high compared to the Tx cost • When Dx is not accurate
  • 12. Proposed institutional processes for co-dependent technologies • A joint Dx-Tx review of “at launch” technologies, to be done by a drug committee to exploit synergies across Dx and Tx • However, need to address the lack of expertise of most drug committees in the Dx area • A separate Dx committee to develop Dx-specific expertise and to assess multiple tests with similar clinical use • However, may be a trade-off if there are not enough decisions to justify a distinct committee • A comprehensive and consistent approach to assessing value of both Dx and Tx
  • 13. International experience: The case of Australia • Until now, Dx and associated Tx assessed via different committees (MSAC and PBAC) • No clear structure for consideration of the interactions and benefits from joint use • New coordinated process and decision framework for “co-dependent technologies” • “Integrated” applications combining information from Dx and Tx manufacturers • Reimbursement decisions are made jointly by PBAC and MSAC to ensure optimal clinical use (Merlin et al., 2012)
  • 14. International experience: The case of NICE in England and Wales • NICE has dedicated-process for stand-alone Dx, which follows that used for drugs very closely • Strong preference for measuring health gains with the QALY • Value dimensions beyond health effects, such as value of information to patients and process-related benefits, are not factored in explicitly • “At launch” combinations are appraised via the drug review programme (TAs) • No explicit consideration of test-related parameters (accuracy, costs) • Value dimensions beyond health effects are not factored in explicitly
  • 15. Conclusions • The use of Dx-Tx combinations can deliver health gains and cost savings within the healthcare systems but also generate broader benefits to patients and society • To ensure efficient use of limited resources health decision makers should take account of the full value generated by health technologies • Clear incentives need to be created to encourage evidence collection • HTA and other decision making systems need coordinated and consistent approach to assessing value of Dx and Tx
  • 16. References Garau, M., Towse, A., Garrison, L., Housman, L., and Ossa, D. (2012) Can and should value based pricing be applied to molecular diagnostics? Research paper 12/03. London: Office of Health Economics [available free at www.ohe.org] Garrison, L.P. and Austin, M.J.F. (2007) The economics of personalized medicine: A model of incentives for value creation and capture. Drug Information Journal. 41(4), 501-509. Merlin, T. et al. (2012) Assessing personalized medicines in Australia: A national framework for reviewing codependent technologies. Medical Decision Making. Online before print: doi:10.1177/0272989X12452341
  • 17. To enquire about additional information and analyses, please contact Martina Garau at mgarau@ohe.org To keep up with the latest news and research, subscribe to our blog, OHE News Follow us on Twitter @OHENews, LinkedIn and SlideShare Office of Health Economics (OHE) Southside, 7th Floor 105 Victoria Street London SW1E 6QT United Kingdom +44 20 7747 8850 www.ohe.org OHE’s publications may be downloaded free of charge for registered users of its website. ©2012 OHE